Pharmaceuticals APAC

APAC Childhood Obesity Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Childhood Obesity Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $310.6 Mn Placeholder estimate
Estimate 2025 $364.9 Mn 20.9% of the global market
Projected 2034 $1.56 Bn 326.9% Adds $1.19 Bn over 9 forecast years
CAGR 2025–2034 17.5% Faster than 79% of 183 Pharmaceuticals markets here
Key players 5
  • APAC is 20.86% of the global market.
  • Among regions, the largest is North America at $971.9 Mn.
  • Fastest growing: APAC (this report) at 17.5% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.19 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Childhood Obesity Treatment Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $310.6 Mn — —
2025 (base) $364.9 Mn +$54.3 Mn —
2026 (forecast) $428.8 Mn +$63.9 Mn +17.5%
2027 (forecast) $503.8 Mn +$75.0 Mn +38.1%
2028 (forecast) $592.0 Mn +$88.2 Mn +62.2%
2029 (forecast) $695.5 Mn +$103.6 Mn +90.6%
2030 (forecast) $817.3 Mn +$121.7 Mn +124%
2031 (forecast) $960.3 Mn +$143.0 Mn +163.2%
2032 (forecast) $1.13 Bn +$168.0 Mn +209.2%
2033 (forecast) $1.33 Bn +$197.5 Mn +263.3%
2034 (forecast) $1.56 Bn +$232.0 Mn +326.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Childhood Obesity Treatment Market Analysis at a glance
Market size, 2025$364.9 Mn placeholder estimate
Forecast, 2034$1.56 Bn placeholder estimate
Growth (CAGR), 2025–203417.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, age and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Rhythm Pharmaceuticals, Kurbo (WW International), Teladoc Health (see all)
Active clinical trials32 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Childhood Obesity Treatment Market Analysis Executive Summary

Childhood obesity treatment includes family programs, nutrition support, medicines and, for some teens, surgery to help children reach a healthier weight.

Key segments of the childhood Obesity Treatment market include treatment (Lifestyle and Behavioral Programs, Medication and Bariatric Surgery) and age (Children 6-11 and Adolescents 12-17).

Bar chart: Asia Pacific Childhood Obesity Treatment market size, 2024–2034, placeholder estimates. $310.6 Mn in 2024, $364.9 Mn in 2025 and $1.56 Bn in 2034, 17.5% CAGR.
Asia Pacific Childhood Obesity Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Childhood Obesity Treatment Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the childhood Obesity Treatment market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the childhood Obesity Treatment market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the childhood Obesity Treatment market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Childhood Obesity Treatment Market in APAC

The childhood Obesity Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Childhood Obesity Treatment Market in APAC

Childhood Obesity Treatment in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], BPOM (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Drug Administration of Vietnam (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28]. ClinicalTrials.gov lists 32 studies on Childhood Obesity Treatment that are recruiting, active or about to start in APAC.⁠[29]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Drug Administration of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

[29] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for childhood Obesity Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Childhood Obesity Treatment right now, from free public sources.

Clinical trials

32 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Obesity (adults), % of adults (WHO)
CountryValueYear
Afghanistan20.62024
Australia30.62024
Bangladesh5.82024
China9.32024
India8.02024
Indonesia11.82024
Japan5.92024
Malaysia23.32024
Myanmar8.12024
Nepal8.02024
New Zealand34.02024
Pakistan24.52024
Philippines9.62024
Singapore17.02024
South Korea8.42024
Thailand16.42024
Vietnam2.42024
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Childhood Obesity Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Childhood Obesity Treatment market in Asia Pacific?
Placeholder estimate: about $364.9 Mn in 2025, rising to about $1.56 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Childhood Obesity Treatment market in Asia Pacific growing?
Placeholder estimate: about 17.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Childhood Obesity Treatment market report cover?
The report splits the market by treatment (Lifestyle and Behavioral Programs, Medication, Bariatric Surgery), age (Children 6-11, Adolescents 12-17) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Childhood Obesity Treatment market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Rhythm Pharmaceuticals, Kurbo (WW International) and Teladoc Health.
What is driving the Childhood Obesity Treatment market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the childhood Obesity Treatment market.
How many clinical trials on Childhood Obesity Treatment are running in Asia Pacific?
32 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Childhood Obesity Treatment?
PubMed lists 54 papers on Childhood Obesity Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on obesity and pediatric

See the topic